submit

Member Login:

submit

Forgot Password? | Register for an Account

Advances in PH Journal

Information about Advances in Pulmonary Hypertension

//

Reviews

Sign in to add a review

0 comments
Leave a Comment

Tweet !function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0];if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src="//platform.twitter.com/widgets.js";fjs.parentNode.insertBefore(js,fjs);}}(document,"script","twitter-wjs");

(function(d, s, id) { var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) return; js = d.createElement(s); js.id = id; js.src = "//connect.facebook.net/en_US/all.js#xfbml=1"; fjs.parentNode.insertBefore(js, fjs); }(document, 'script', 'facebook-jssdk'));

Vol 11, No 3 (Fall 2012)

Download This Issue

Program Overview:

Pulmonary arterial hypertension (PAH), an incurable disease, is characterized by medial hypertrophy,

intimal fibrosis, and in situ thrombi in small muscular pulmonary arteries. PAH was considered a rapidly fatal illness with a median survival of 2.8 years in the 1980s when no evidence-based therapies were available. Since then the treatment of this disease has made tremendous advances, and in the last 10 years the discovery of new medications have positively influenced the prognosis and survival of patients with PAH.

This self-study activity is based on 7 articles that summarize presentations at PHA's 10th International Pulmonary Hypertension Conference and Scientific Sessions in Orlando June 22-24, 2012.

Target Audience:

This self-study activity is appropriate for cardiologists, pulmonologists, rheumatologists, and

other physicians who treat patients with PH.

Learning Objectives:

Upon completion of this activity, participants will be able to:

1. Define the global burden of pulmonary hypertension.
2. Define the cellular metabolic changes seen in the development of PAH.
3. Describe the effects of altered cellular metabolism on BMPR2 signaling.
4. Outline the hypothesis regarding PAH as a systemic disease.

Self-Assessment Examination:

This issue of *Advances in Pulmonary Hypertension* does not provide CME credits. A quiz, answer key, evaluation form, and answers appear on pages 133 and 134 so you may assess yourself regarding your accomplishment of the learning objectives for these articles. For CME opportunities from other PHA programs, go to http://www.phaonlineuniv.org/.

Faculty

Chair

Karen Fagan, MD
University of South Alabama
Mobile, AL

Contributing Authors

Ghazwan Butrous, MB, ChB, PhD
University of Kent, Canterbury
Kent, United Kingdom

Timothy M. Moore, MD, PhD
Division of Lung Diseases
National Heart, Lung, and Blood Institute
National Institutes of Health
Bethesda, MD

John H. Newman, MD
Division of Pulmonary and Critical Care
Medicine
Vanderbilt University School of Medicine
Nashville, TN

Marlene Rabinovitch, MD
Stanford University School of Medicine
Stanford, CA

Mourad Toporsian, PhD
Center for Vascular Biology Research
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, MA

James D. West, PhD
Vanderbilt University
Nashville, TN

Sebastien Bonnet, PhD
Laval University
Quebec City, Quebec, Canada

To ensure balance, independence, objectivity, and scientific rigor in all its educational activities, all faculty participating in this activity are expected to disclose to the audience any financial interest or other potential conflict. Each author was asked to complete a disclosure information form for this activity. Disclosures are reported below:

Dr Fagan has served as a consultant/ advisory board member/or on the steering committee for Gilead, Pfizer, Novartis, and Bayer. She has been on the speaker's bureau for Gilead, Simply Speaking, and PHA. She has received institutional grants/research support from Bayer Healthcare, Actelion Pharmaceuticals, and Gilead.

Drs Bonnet, Moore, Newman, Rabinovitch, Toporsian, and West indicate no significant relationships to disclose.

Dr Butrous is a consultant or serves on the speaker's bureau for Novartis Pharmaceuticals and Bayer HealthCare and is a stock shareholder in Pfizer, Inc.

PREVIOUS * NEXT

Log In to Comment

Comments

Related Resources

- Pulmonary Hypertension Care Centers
- Medication and Drug Exposure in PH Patients
- Near-Term Novel Therapies for PAH
- 2014 International Conference and Scientific Sessions - Abstracts
- 2015 (Vol 14, No 1): Table of Contents

Delphine Yung, MD

PHA Scientific Leadership Council Member
Associate Professor of of Pediatrics
Seattle Children's
Seattle, Washington

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910
301-565-3004 | PHAOnlineUniv@PHAssociation.org